{"schema_version":"secwatch.filing_event.v1","accession":"0001809519-25-000073","form_type":"8-K","ticker":"GDRX","cik":"0001809519","company_name":"GoodRx Holdings, Inc.","filed_at":"2025-05-07T23:59:59+00:00","discovered_at":"2026-05-14T18:02:49.815030+00:00","generated_at":"2026-05-22T08:43:21.685864+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"GoodRx Q1 2025 revenue in-line at $203M; raises FY adjusted EBITDA guidance","bullets":["Revenue $203.0M, net income $11.1M (net income margin 5.4%).","Adjusted EBITDA $69.8M (34.4% margin) beat guidance; FY adjusted EBITDA expectations raised.","Adjusted Net Income $34.4M (16.9% margin).","Maintains FY 2025 revenue guidance range.","Over 7 million consumers of prescription-related offerings at quarter end."],"urls":{"canonical":"https://secwatch.observer/filing/0001809519-25-000073","json":"https://secwatch.observer/filing/0001809519-25-000073.json","markdown":"https://secwatch.observer/filing/0001809519-25-000073.md","text":"https://secwatch.observer/filing/0001809519-25-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000073/0001809519-25-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1809519/000180951925000073/gdrx-20250507.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-22T08:43:21.685864+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}